Literature DB >> 17698415

Diagnosis and management of fetal growth restriction: the role of fetal therapy.

Lisa Hui1, Daniel Challis.   

Abstract

Fetal growth restriction remains a major cause of perinatal morbidity and mortality in modern obstetric practice. Placental insufficiency is the most common association, but is often a diagnosis of exclusion. Currently, no treatment can ameliorate or reverse established growth restriction: maximising gestational age and judicious timing of steroid administration and delivery are the primary tasks for the obstetrician. Although comprehensive surveillance of the preterm fetus now includes ductus venosus Doppler studies, its effectiveness in timing delivery has yet to be confirmed in randomised controlled trials. More basic research on the regulation of fetal growth is needed before specific therapies for established growth restriction can be developed.

Entities:  

Mesh:

Year:  2007        PMID: 17698415     DOI: 10.1016/j.bpobgyn.2007.06.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  8 in total

1.  Establishment of reference ranges for ductus venosus waveform indices in the Japanese population.

Authors:  Yasuhiro Takahashi; Keisuke Ishii; Keisuke Honda; Akira Kikuchi; Koichi Takakuwa; Kenichi Tanaka
Journal:  J Med Ultrason (2001)       Date:  2010-07-03       Impact factor: 1.314

Review 2.  Umbilical Cord Blood-Derived Exosomes in Maternal-Fetal Disease: a Review.

Authors:  Jingyi Liu; Wei Sun; Caixia Liu; Quan Na
Journal:  Reprod Sci       Date:  2022-02-14       Impact factor: 3.060

3.  Tadalafil treatment for fetuses with early-onset growth restriction: a protocol for a multicentre, randomised, placebo-controlled, double-blind phase II trial (TADAFER IIb).

Authors:  Shintaro Maki; Hiroaki Tanaka; Sho Takakura; Masafumi Nii; Kayo Tanaka; Toru Ogura; Mayumi Kotera; Yuki Nishimura; Satoshi Tamaru; Takafumi Ushida; Yasuhiro Tanaka; Norihiko Kikuchi; Tadatsugu Kinjo; Hiroshi Kawamura; Mayumi Takano; Koji Nakamura; Sachie Suga; Michi Kasai; Osamu Yasui; Kenji Nagao; Yuka Maegawa; Tomomi Kotani; Masayuki Endo; Ichiro Yasuhi; Shigeru Aoki; Yoichi Aoki; Yoshio Yoshida; Masahiko Nakata; Akihiko Sekizawa; Tomoaki Ikeda
Journal:  BMJ Open       Date:  2022-06-14       Impact factor: 3.006

4.  Evaluation of first-trimester neutrophil-lymphocyte ratio and platelet-lymphocyte ratio values in pregnancies complicated by intrauterine growth retardation.

Authors:  Harun Egemen Tolunay; Hasan Eroğlu; Erol Nadi Varlı; Mustafa Akşar; Dilek Şahin; Aykan Yücel
Journal:  Turk J Obstet Gynecol       Date:  2020-07-29

Review 5.  Regulation of Placental Development and Its Impact on Fetal Growth-New Insights From Mouse Models.

Authors:  Laura Woods; Vicente Perez-Garcia; Myriam Hemberger
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-27       Impact factor: 5.555

6.  Maternal Blood Concentration of Tadalafil and Uterine Blood Flow in Pregnancy.

Authors:  Hiroaki Tanaka; Shintaro Maki; Shoichi Magawa; Masafumi Nii; Kayo Tanaka; Kenji Ikemura; Kuniaki Toriyabe; Tomoaki Ikeda
Journal:  Medicina (Kaunas)       Date:  2019-10-21       Impact factor: 2.430

7.  Tadalafil Treatment Ameliorates Hypoxia and Alters Placental Expression of Proteins Downstream of mTOR Signaling in Fetal Growth Restriction.

Authors:  Kyoka Tsuchiya; Kayo Tanaka; Hiroaki Tanaka; Shintaro Maki; Naosuke Enomoto; Sho Takakura; Masafumi Nii; Kuniaki Toriyabe; Shinji Katsuragi; Tomoaki Ikeda
Journal:  Medicina (Kaunas)       Date:  2020-12-21       Impact factor: 2.430

8.  TADAFER II: Tadalafil treatment for fetal growth restriction - a study protocol for a multicenter randomised controlled phase II trial.

Authors:  Takashi Umekawa; Shintaro Maki; Michiko Kubo; Hiroaki Tanaka; Masafumi Nii; Kayo Tanaka; Kazuhiro Osato; Yuki Kamimoto; Satoshi Tamaru; Toru Ogura; Yuki Nishimura; Mayumi Kodera; Chisato Minamide; Masakatsu Nishikawa; Masayuki Endoh; Tadashi Kimura; Tomomi Kotani; Masamitsu Nakamura; Akihiko Sekizawa; Tomoaki Ikeda
Journal:  BMJ Open       Date:  2018-10-30       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.